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A b s t r a c t  
The purpose of the present study was to develop and optimize controlled release (CR) matrix tablets 
of Entacapone trilayer tablets to achieve zero-order drug release for sustained plasma 
concentration. Entacapone tablets were prepared by direct compression and consist of middle active 
layer with different grades of hydroxypropylmethylcellulose (HPMC), xanthan gum, ethyl cellulose; 
upper and lower layers were prepared with Carnauba wax, xanthan gum, sodium CMC and DCP. 
The tablets were also evaluated for physicochemical characteristics and release kinetics. The 
physicochemical characteristics of the prepared tablets were satisfactory. The developed drug 
delivery systems showed prolonged drug release rates over a period of 24 h. The release profile of 
the optimized formulation (HF14) was described by the Zero-order and Higuchi model. In-vivo 
(Rabbit) bioavailability studies were carried out on the optimized formulation (HF14) as marketed 
conventional release product as a reference standard. Entacapone was available in plasma within 
an hour after oral administration of reference product. The Tmax of the optimized formulation was 
significantly different (p < 0.05) from that of the marketed product. Low Tmax value for the reference 
product (1.00μ0.01h) indicates rapid absorption while the higher Tmax of the optimized (4.01μ0.04h) 
suggests slower absorption. This delayed absorption of test preparation is most likely due to the 
sustained release of the drug. A fair correlation between the in vitro dissolution profile and in vivo 
pharmacokinetic profile of the optimized formulation was observed. The results indicate that the 
approach used could lead to a successful development of a controlled release formulation of the 
drug. These results also demonstrated the suitability of three-layered tablet formulation of 
Entacapone to provide controlled release for prolonged period of time and improved linearity for 
Entacapone in comparison to marketed product with conventional drug release profile. 
Keywords: Entacapone, Trilayer matrix tablet, HPMC, Xanthan gum, Geomatrix, In-vivo 
bioavailability studies. 
Introduction 
Controlled release pharmaceutical systems have been developed 
and studied to improve the performance of drugs and in particular 
to increase their pharmacological effect and reduce any side 
effects [1]. The basic characteristic of the systems is that the rate 
of drug absorption may be adjusted through a controlled rate of 
drug release from the dosage forms. A number of design options 
are available to control or modulate drug release from a drug 
delivery system. Most oral controlled release dosage forms fall in 
the category of matrix, reservoir or multi-layer systems. Lately, 
multi-layer matrix systems are gaining importance in the design of 
oral sustained drug delivery systems. A multi-layer system 
consists, usually, of a hydrophilic matrix core containing the active 
ingredient and one or two impermeable or semi-permeable 
polymeric coatings (barrier-layer) applied on one or both faces of 
the core during tabletting [2, 3, & 4]. 
The barrier layers delay the interaction of active solute with 
dissolution medium, by limiting the surface available for the solute 
release and at the same time controlling solvent penetration rate 
[5,6]. In the device, the coat layers prevent the water penetration 
through the protected core for some duration. After this phase 
during the subsequent dissolution process, the swollen barriers 
erode and the surface available for drug release slowly increases. 
In this way the decrease of delivery rate due to the increase in 
diffusion path length is counter balanced by the simultaneous 
increase of the area available for drug release [7,8].  
The use of naturally occurring biocompatible gums has been the 
focus of recent research activity in the design of dosage forms for 
oral controlled release administration, and hydrophilic polymers 
matrix systems are widely used because of their flexibility to 
provide a desirable drug release profile, cost effectiveness, and 
broad regulatory acceptance [9]. Xanthan gum (XG) is soluble in 
water, anionic hetero polysaccharide and to be sensitive to pH and 
ionic strengths. It swells in gastric fluid to produce a highly viscous 
layer around the tablet through which the drug can slowly diffuse10 
and is used for the fabrication of matrices with uniform drug release 
characteristics [11&12].  
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Geomatrix technology: There have been different approaches to 
achieve zero-order drug release from dosage forms for sustained 
plasma concentration. Among different approaches to achieve 
zero-order release from hydrophilic matrix technologies, multilayer 
matrices have been widely evaluated and developed for 
commercial products under the trade name of Geomatrix. The 
technology makes use of bilayer or trilayer tablets to modulate the 
release and to achieve constant release [13].  
Entacapone is a selective, reversible catechol-O-methyl 
transferase (COMT) inhibitor, used in the treatment of Parkinson's 
disease.  It is a member of the class of nitrocatechols. The principal 
therapeutic action of the COMT inhibitors is to block this peripheral 
conversion of levodopa to 3-O-methyl DOPA, increasing both the 
plasma half-life of levodopa as well as the fraction of the dose that 
reaches the CNS [14]. 
The short half life of Entacapone necessitated for fabricating 
extended release matrix tablets to provide a therapeutic amount of 
drug and maintain the desired drug concentration i.e. the drug-
delivery system should deliver drug at a rate dictated by the needs 
of the body over a specific period of time. Sustained release tablets 
are intended to take once or twice daily, when compared with 
conventional dosage forms that may have to take three or four 
times daily to achieve the same therapeutic effect. The objective of 
the present study was to develop a trilayered tablet of Entacapone 
with different hydrophobic and hydrophilic polymers. The results 
indicate that the optimized trilayered Entacapone tablet can be 
successfully used for treatment of ParkinsonÊs disease. 
Materials and methods 
Materials 
Entacapone pure drug was generous gift from Aurobindo Pharma 
Limited, Hyderabad, India. Sodium carboxyl methyl cellulose, 
HPMC K 4 M, HPMC K 15 M & HPMC K 100 M were obtained from 
Rubicon labs, Mumbai. Xanthan gum and Carnauba wax were 
gifted from MSN Labs Ltd. Hyderabad. Entacapone (200mg) film 
coated tablets were purchased from Orion Pharma Ltd, Mumbai. 
All other chemicals used were of analytical grade. 
Methods 
Pre-compression parameters 
Angle of Repose: In powder frictional forces can be measured with 
the help of angle of repose. Angle of repose is the maximum angle 
which is possible between surface of pile of powder and horizontal 
plane i.e. height. 
tanď= h/r 
ď=tan-1h/r 
Where ď = Angle of repose 
h= height of pile 
r = radius of pile [15]. 
CarrÊs compressibility Index: The propensity of the powder to be 
compressed is measured by compressibility index and it also helps 
in measurement of settling property and inter particulate 
interaction. 
CarrÊs index (%) = ρt ă ρo* 100 / ρt 
Where ρt = Tapped density gram/ml 
ρo = Bulk density gram/ml 
 
Bulk Dentistry: It is denoted by ρb and is defined as mass of 
powder divided by bulk volume (The United States Pharmacopeial 
Convention Stage 6 Harmonization Official December 1, 2012, 
616.).  
Tapped Density: An increased in bulk density which is attained 
after mechanical tapping in measuring cylinder is called as tapped 
density. 
Tapped density= Weight of powder taken/ Tapped Volume.  
Hausner Ratio: The propensity of the powder to be compressed is 
measured by Hausner ratio. Interparticulate interaction and settling 
property can be measured by Hausner ratio. 
Hausner ratio= Tapped density/ Bulk density 
Hausner ratio= Vo/Vf 
Where, Vo= Unsettled apparent volume 
Vf= Final tapped volume [16] . 
Formulation of controlled release Entacapone trilayer 
matrix tablets 
The trilayered matrix tablets of Entacapone were prepared by 
direct compression method. The first step in the formulation was to 
develop the middle active layer so as to give at least 90%drug 
release during 12hours. The release profile of this layer might not 
be of constant rate type but would be preferably of constantly 
falling rate type. This layer would then be sandwiched between 
barrier layers (Upper & Lower layers) so as to continue the drug 
release for 24 h.   
Preparation of middle active layer  
Sixteen formulations (F1-F16) for active layer were prepared by 
direct compression method using polymers like different HPMC 
grades, Xanthan gum, Sodium CMC, EC. All the formulations were 
varied in concentration of polymers, talc (1.5mg) & magnesium 
stearate (1.5mg) constituted in all the formulations.  These 
materials were screened through Æ60 and mixed together in motor 
by using pestle. Final mixtures were compressed by using 12mm 
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Table 1: Formulation trails for middle active layer (F1-F16) 
INGREDIENTS (mg) F1  
F2 
 
F3 
 
F4
 
F5
 
F6
 
F7
 
F8
 
F9
 
F10
 
F11 
 
F12 
 
F13
 
F14
 
F15
 
F16
 
Entacapone 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200
HPMC K 4M 50 55 60 --- --- ---- 25 30 ---- ---- ---- ---- ---- ---- ---- ----
HPMC K 15M --- ---- ---- 50 55 60 45 40 ---- ---- ---- ---- ---- ---- ---- ----
HPMC K 100M --- --- --- ---- --- ---- ---- ---- 40 45 50 55 60 62.5 65 67.5
Ethyl cellulose 22 30 32 22 30 32 15 15 40 35 22 30 32 22.5 22.5 22.5
Xanthan gum 20 22 25 20 22 25 30 32 15 17.5 20 22 25 30 30 30
Sodium carboxy methyl cellulose 25 15 10 25 15 10 15 15 27 21.5 25 15 10 12 10 12
Dibasic  calcium phosphate 30 25 20 30 25 20 17 15 25 27 30 25 20 20 19.5 15
     
diameter flat punches on a sixteen station rotary tablet press. 
Formulation of active layer was depicted in Table 1. The prepared 
tablets were subjected to dissolution studies. 
Preparation of upper and lower layers 
The barrier layers was formulated employing hydrophobic 
swellable polymer natural wax i.e. carnauba wax the swelling 
erosion modelling fillers which include water soluble DCP, EC and 
Xanthan gum. The procedure adopted to make the compacts was 
via direct compressions. For the first procedure the wax, xanthan 
gum and the filler was mixed in mortar and lubricated with 
magnesium stearate. Formulation of upper and lower layers was 
depicted in Table 2.  
Formulation of Entacapone tryilayer tablets 
The powder mixtures required for active and barrier layers were 
weighed accurately and thoroughly mixed using mortor and pestle 
for about 20 minutes. Initially, the volume of die cavity; (12mm, 
round) was adjusted equivalence to the weight of trilayered matrix 
tablets (600mg). Then the pre weighed amount of powder 
equivalent to bottom layer (125mg) was taken and placed in the die 
cavity and slightly compressed for uniform spreading. The upper 
punch was lifted up and the granules equivalent to 200mg of the 
drug was placed over the bottom layer in the die cavity and again 
slightly compressed. The remaining volume of the die cavity was 
filled with pre weighed (125mg) amount of powder equivalent to top 
layer and compressed with the full force of compression on rotary 
tablets press to obtain tri-layered tablets. Tri-layered matrix tablets 
of each composition were compressed and tested for their friability, 
Hardness, drug content and drug release characteristics with a 
suitable number of tablets for each test.  
 
Table 2: Composition of Entacapone trilayer matrix tablet   
INGREDIENTS       AF14 BF14 CF14 DF14 EF14 FF14 GF14 HF14
MIDDILE ACTIVE LAYAER (F14) (mg)
Entacapone 200 200 200 200 200 200 200 200
HPMC K 100M 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5
Ethyl cellulose 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5
Xanthan gum 30 30 30 30 30 30 30 30
Sodium CMC 12 12 12 12 12 12 12 12 
Dibasic  calcium phosphate 20 20 20 20 20 20 20 20
                                                UPPER AND LOWER LAYER(mg)
Carnauba wax 20 25 30 35 40 42.5 45 50
Xanthan gum  40 40 38 35 35 32.5 30 30
Ethyl cellulose  12 10 14 12 15 12 12 12
Dibasic calcium phosphate 50 47 40 40 32 35 35 30
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
 
Evaluation of trilayer matrix tablets of Entacapone 
Hardness 
 
 
 
Hardness of ten randomly picked tablets was determined using 
Monsanto hardness tester. 
Friability 
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A sample of twenty randomly selected tablets were accurately 
weighed and placed in a Roche Friabilator. The Friabilator was 
operated for 4 min at a speed of 25 rpm. The tablets were removed 
from the Friabilator, de-dusted and reweighed. The percent loss in 
weight due to abrasion and impact was calculated as, 
 
% Friability = (Loss in weight/ Initial weight) X 100. 
Weight variation 
The weight variation test was performed as per the USP. Twenty 
randomly taken tablets were weighed together and the average 
weight was determined. Each tablet was then weighed individually 
and deviation from average weight was calculated.  
Drug content / Assay 
Five tablets were weighed individually and powdered. Then the 
powder of tablet equivalent to 200mg was weighed and dissolved 
in phosphate buffer pH 5.5, the solution was filtered and diluted 
using phosphate buffer pH 5.5 and then the drug content was 
analyzed using UV spectrophotometer at 377nm.  
Swelling & Erosion studies 
Swelling experiment was conducted on the prepared tablets using 
USP dissolution apparatus II at rotational speed of 50 rpm. The 
medium used was 900ml phosphate buffer pH 5.5 at 370C. The 
swelling study was done upto 10h. The tablets were removed using 
a small basket and swollen weight of each tablet was determined. 
The percentage of swelling was calculated according to the 
formula: 
Percentage of swelling = (S/R) X 100                            
In-vitro drug release profile 
In vitro drug release studies for developed trilayer matrix tablets 
were carried out by using dissolution apparatus II paddle type 
(Electrolab TDL-08L). The drug release profile was studied in 
500ml Phosphate buffer pH 5.5 at 37μ 0.50C temperature. The 
amount of drug release was determined by UV visible 
spectrophotometer (Shimadzu UV 1800) at 377nm. 
Drug release kinetics  
To describe the kinetics of the drug release from matrix tablet, 
mathematical models such as Zero-order, First order and Higuchi, 
models were used. The criterion for selecting the most appropriate 
model was chosen on the basis of the goodness-or fit test. 
Drug-excipient compatibility studies 
Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectra for pure drug, physical mixture and optimized 
formulations were recorded using a Fourier transform Infrared 
spectrophotometer. The analysis was carried out in Shimadzu-IR 
Affinity 1 Spectrophotometer. The samples were dispersed in KBr 
and compressed into disc/pellet by application of pressure. The 
pellets were placed in the light path for recording the IR spectra. 
The scanning range was 400-4000 cm-1 and the resolution was 1 
cm-1. 
Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. Samples 
were accurately weighed and heated in sealed aluminium pans at a 
rate of 10ĈC/min between 25 and 350ĈC temperature rang under 
nitrogen atmosphere. Empty aluminium pan was used as a 
reference. 
Stability studies  
The stability study of the formulated trilayer tablets were carried out 
under different conditions according to ICH guidelines using 
stability chamber (REMI make). Accelerated Stability studies were 
carried out at 40 0C / 75 % RH for the best formulations for 6 
months. The tablets were characterized for the hardness, friability, 
drug content and cumulative % drug release during the stability 
study period.  
Pharmacokinetic studies  
Animal Preparation  
Male rabbits (weighing 2-3 kg) were selected for this study. 
Animals were maintained at room temperature 250C, Relative 
Humidity 45% and 12 h alternate light and dark cycle with 100 % 
fresh air exchange in animal rooms, uninterrupted power and water 
supply and rabbits were fed with standard diet and water ad 
libitum. The animals that were healthy during the period of 
quarantine were used for experiment. The protocol of animal study 
was approved by the Institutional Animal Ethics Committee (IAEC 
NO: P34/VCP/IAEC/2015/2/DBP/AE12). 
In vivo study design 
The rabbits were randomly divided into two groups each group 
contains three animals. The group A was administered with 
prepared Entacapone matrix tablets (200mg), Marketed product 
was administered group B with equivalent dose of animal body 
weight. Blood samples (approximately 0.5ml) were obtained with 
syringes by marginal ear vein at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 20 
and 24hrs post dose. During collection, blood sample has been 
mixed thoroughly with heparin in order to prevent blood clotting. 
Plasma was separated by centrifugation of the blood at 5000 rpm 
in cooling centrifuge for 5min to 10 minutes and stored frozen at 
î20ĈC until analysis.  
Preparation of Plasma Samples for HPLC Analysis  
Rabbit plasma (0.5 ml) samples were prepared for chromatography 
by precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation the ethanol was 
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transferred into a clean tube. The precipitate was re suspended 
with 1 ml of Acetonitrile by vortexing for 1 min. After centrifugation 
(5000 ă 6000 rpm for 10 min), the Acetonitrile was added to the 
ethanol and the organic mixture was taken to near dryness by a 
steam of nitrogen at room temperature. For HPLC C18 column with 
5 μm particle size and the Mobile Phase consisting of 30mM 
phosphate buffer (pH 2.75) : acetonitrile :: 62:38. The flow rate was 
1.0 ml/min and the effluents were monitored at 315 nm with 
rofecoxib as internal standard. The retention time was 8.3 min and 
10.7min for Entacapone and rofecoxib respectively. 
Pharmacokinetic analysis   
The pharmacokinetic parameters, peak plasma concentrations 
(Cmax) and time to reach peak concentration (tmax) were directly 
obtained from concentration time data. In the present study, AUC0-t 
refers to the AUC from 0 to 24 hrs, which was determined by linear 
trapezoidal rule and AUC0-α refers to the AUC from time at zero 
hours to infinity.  
The AUC0-α was calculated using the formula AUC0-t + [Clast/K] 
where C last is the concentration in μg/ml at the last time point and 
K is the elimination rate constant. Various pharmacokinetic 
parameters like area under the curve [AUC], elimination half life 
(tó). Volume of distribution (Vd), total clearance (ClT) and mean 
residence time for each subject using a non compartmental 
pharmacokinetic programme. The pharmacokinetic parameters 
were performed by a non compartmental analysis using Win Nonlin 
3.3® pharmacokinetic software (Pharsight Mountain View, CA 
USA). All values are expressed as the mean μSD. Statistical 
analysis was performed with Graph Pad InStat software (version 
3.00, Graph Pad Software, San Diego, CA, USA) using one-way 
analysis of variance (ANOVA) followed by TukeyăKramer multiple 
comparison test. Difference with p<0.05 was considered 
statistically significant. 
Results and Discussion 
Pre-compression parameters 
All the powder mixture belonging to different formulations was 
tested for micrometrics    studies in order to determine the flow 
properties. All the formulations AF14 to HF14 showed good flow 
properties, the results are summarized in Table 3. 
 
Table 3: Powder flow properties of Entacapone, powder blends of active layer and barrier layer polymers 
Powder  properties AF14 BF14 CF14 DF14 EF14 FF14 GF14 HF14
Bulk density (g/cc) 0.7151μ0.04 0.7121μ0.46 0.512μ0.02 0.7050μ0.14 0.714μ0.56 0.684μ0.78 0.695μ0.02 0.704μ0.56
Tapped density(g/cc) 0.787μ0.10 0.790μ0.93 0.629μ0.17 0.767μ0.2 0.795μ0.93 0.746μ0.82 0.781μ0.048 0.796μ0.93
Angle of repose (o) 33.69μ0.63 34.93μ0.66 33.12μ0.63 31.89μ0.43 24.39μ0.66 33.09μ0.27 28.15μ0.02 26.39μ0.66
CarrÊs index 8.09μ0.91 8.02μ0.93 9.49μ0.51 8.29μ0.91 8.35μ0.94 7.62μ0.58 7.28μ0.33 8.15μ0.94
 
Preparation of middle active layer  
 
 
 
The matrix tablets of Entacapone were prepared without the barrier 
layers. All the formulation trails were subjected to in vitro 
dissolution to determine the release profiles. 
Table 4: Dissolution profile of different formulations Entacapone active layer (F1-F8) 
TIME (h) F1 F2 F3 F4 F5 F6 F7 F8 
1 27.12μ 
0.04 
27.56μ 
0.02 
38.2μ
0.01 
19.12μ
0.01 
15.4μ
0.01 
25.4μ
0.01 
28.7μ 
0.01 
10.3μ
0.01 
2 42.6μ 
0.01 
39.12μ 
0.02 
48.2μ
0.04 
39.2μ
0.02 
38.3μ
0.02 
35.2μ
0.02 
37.4μ 
0.02 
25.1μ
0.02 
4 63.6μ 
0.02 
42.7μ 
0.01 
59.4μ
0.02 
55.12μ
0.01 
42.7μ
0.02 
47.6μ
0.01 
64.5μ 
0.04 
35.3μ
0.04 
6 76.12μ 
0.01 
57.2μ 
0.05 
75.11μ
0.01 
64.4μ
0.02 
54.4μ
0.01 
60.4μ
0.02 
72.8μ 
0.04 
55.9μ
0.04 
8 83.02μ 
0.04 
75.11μ 
0.03 
86.2μ
0.04 
72.1μ
0.04 
79.11μ
0.04 
65.3μ
0.03 
82.6μ 
0.02 
68.3μ
0.05 
10 89.2μ 
0.05 
89.12μ 
0.01 
88.4μ
0.03 
79.3μ
0.04 
89.2μ
0.02 
72.7μ
0.01 
88.2μ 
0.01 
69.6μ
0.01 
12 94.9μ 
0.01 
95.2μ 
0.02 
92.1μ
0.02 
89.6μ
0.03 
94.3μ
0.01 
86.9μ
0.02 
92.4μ 
0.01 
70.8μ
0.03 
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Table 5:  Dissolution profile of different formulations Entacapone active layer (F9-F16) 
TIME (h) F9 F10 F11 F12 F13 F14 F15 F16
1 13.8μ0.01 15.7μ0.01 25.5μ0.02 17.5μ0.01 31.8μ0.01 30.5μ0.01 14.8μ0.04 14.5μ0.02
2 35.4μ0.03 40.4μ0.02 39.4μ0.01 25.8μ0.02 42.4μ0.01 40.7μ0.02 32.7μ0.04 32.2μ0.02
4 55.6μ0.05 58.3μ0.04 52.6μ0.04 45.3μ0.04 62.8μ0.02 72.4μ0.01 55.6μ0.01 55.4μ0.01
6 65.2μ0.04 67.7μ0.04 65.2μ0.04 50.4μ0.01 79.1μ0.04 80.4μ0.04 65.4μ0.02 75.4μ0.04
8 69.6μ0.01 75.2μ0.01 72.7μ0.02 57.8μ0.02 86.6μ0.02 88.2μ0.01 82.2μ0.01 85.3μ0.04
10 72.8μ0.04 86.8μ0.02 87.4μ0.01 82.6μ0.02 92.8μ0.04 93.2μ0.01 88.1μ0.03 89.2μ0.03
12 85.3μ0.01 92.7μ0.01 96.5μ0.02 96.2μ0.01 96.5μ0.01 99.6μ0.04 93.7μ0.01 95.2μ0.01
 
 
                                                 Figure 1: In vitro Dissolution profile of F1-F8 Entacapone active layer formulations    
 
 
                                          Figure 2: In vitro Dissolution profile of F9-F16 Entacapone active layer formulations    
 
From the above results, among all the formulations the formulation 
F14 was decided as optimized formulation for active layer based 
on the highest drug release i.e. 99.6μ0.04 within 12hrs when 
compared with other preparations (Table 4&5; Figure 1 & 2). 
Formulation F14 was choosen as active layer for further studies.  
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Evaluation of trilayer matrix tablets of Entacapone 
 
Figure 3: Entacapone trilayer matrix tablets 
 
 
The Entacapone trilayer matrix tablets are shown in Figure 3. 
Sustained release tablets generally have hardness in the range of 
7-10 kg/cm2.   In case of trilayer tablets the hardness of the tablets 
was found to be 7.2 to 8.4    kg/cm2. The friability of the 
formulations was found to be less than 1% and hence the tablets 
with lower friability may not break during handling on machines and 
or shipping. All the batches of the tablets complied with the weight 
variation limits as per the IP. The drug content in different 
formulation was highly uniform and the results are depicted in 
Table 6. 
                                                             Table 6: Physical evaluation of Entacapone trilayer tablets 
Formulation code Hardness(kg/cm2) Friability(%) Weight  variation (mg) % Drug content 
AF14 7.4μ0.23 0.35 596μ20 98.1 
BF14 7.9μ0.45 0.27 599μ20 97.8 
CF14 8.4μ0.47 0.45 595μ20 98.4 
DF14 8.1μ0.12 0.16 594μ20 96.6 
EF14 7.2μ0.49 0.32 597μ20 98.4 
FF14 7.8μ0.28 0.46 595μ20 97.9 
GF14 7.6μ0.15 0.37 596μ20 97.1 
HF14 7.2μ0.85 0.22 598μ20 98.9 
 
Swelling studies 
In phosphate buffer pH 5.5, HPMC showed good swelling property. 
In trilayer tablets of Entacapone, HF14 showed highest degree of 
swelling index 219.43%, where as in AH14 showed leased swelling 
with a swelling index of 134.68%.     
In vitro dissolution studies of Entacapone Trilayer 
tablets  
 
 
 
The release of Entacapone from different formulations was carried 
out in phosphate buffer pH 5.5 and the results are depicted in 
Table. The trilayer tablets extended the drug release upto 24 hrs. 
The highest drug release was found in the formulation HF14 i.e 
98.29% within 24 h. HF14 was found to be optimized formulation 
based on the dissolution and other evaluation parameters. The 
results are shown in Table 7 & Figure 4. The comparison of 
marketed product Entacapone (200mg) film coated tablet and 
optimized formulation HF14 was shown in Figure 5. The drug 
release from marketed product was 99% within 60min. 
Table 7:  In-vitro cumulative % drug release studies of Entacapone trilayer tablets   
TIME    (h) AF14 BF14 CF14 DF14 EF14 FF14 GF14 HF14  
1 12.34μ0.01 14.22μ0.04 16.21μ0.04 18.47μ0.05 6.16μ0.01 7.85μ0.04 13.22μ0.04 12.49μ0.04 
2 22.11μ0.02 18.21μ0.05 18.23μ0.05 24.54μ0.05 12.28μ0.02 12.25μ0.05 25.32μ0.02 24.52μ0.04 
4 37.15μ0.03 36.32μ0.04 21.28μ0.05 30.43μ0.05 36.38μ0.02 20.23μ0.05 36.35μ0.03 33.35μ0.03 
6 45.25μ0.05 48.15μ0.04 33.79μ0.05 55.25μ0.04 42.45μ0.03 27.54μ0.05 49.62μ0.04 49.53μ0.05 
8 54.16μ0.09 56.42μ0.08 48.53μ0.05 69.45μ0.02 58.98μ0.04 48.15μ0.04 63.32μ0.05 55.54μ0.07 
12 60.34μ0.05 74.12μ0.05 56.75μ0.06 70.74μ0.03 69.99μ0.05 50.75μ0.05 74.46μ0.05 62.59μ0.05 
16 69.75μ0.03 82.24μ0.04 74.68μ0.06 81.65μ0.03 75.55μ0.04 72.32μ0.01 84.53μ0.04 72.63μ0.05 
20 80.24μ0.05 90.21μ0.05 82.95μ0.07 90.85μ0.02 80.20μ0.05 87.22μ0.05 89.15μ0.06 86.53μ0.06 
24 86.12μ0.04 91.22μ0.02 93.45μ0.01 95.25μ0.02 90.24μ0.03 94.24μ0.04 93.55μ0.04 98.29μ0.09 
Potturi, International Journal of Drug Delivery 7 (3) 155-166 [2015] 
 
 
  
PAGE | 162 |
 
 
 
Figure 4: Comparative % drug release profile of AF14-HF14 
 
 
 
Figure 5: Cumulative percentage drug release of Entacapone from marketed product and optimized formulation HF14 
 
Table 8: Drug release kinetics of optimized (HF14) and Marketed product 
Formulation code Zero order First order Higuchi model 
HF14 0.979 0.717 0.913
Marketed product 0.806 0.968 ------
 
In the present investigation drug release mechanism is best fitting 
to zero order and Higuchi model because regression coefficient 
was seen closest to 1 in these models which conforms diffusion 
assisted mechanism of release. The marketed product Entacapone 
(200mg) was explained by first order kinetics as the plot showed 
highest linearity (rñ=0.968) as the drug release was best fitted in 
first order kinetics.  
Characterization
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FT-IR: 
 
       Figure 6:   FT-IR spectrum of pure drug Entacapone 
 
 
      Figure 7:  FT-IR spectrum of pure drug and other polymers 
 
 
      Figure 8:   FT-IR spectrum of optimized formulation HF14 
 
Overall there was no alteration in peaks of Entacapone pure drug 
(Figure 6) and optimized formulation (Figure 7), suggesting that 
there was no interaction between drug & excipients. FT-IR 
spectrum of pure drug and other polymers are shown in (Figure 8). 
There is additional peaks appeared or disappeared hence no 
significant changes in peaks of optimized formulation was 
observed when compared to pure drug indicating absence of any 
interaction. 
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DSC studies 
 
Figure 9: DSC thermogram of Entacapone pure drug (A) and 
optimized formulatin HF14 (B) 
DSC was used to detect interaction between Entacapone and 
excipients. The thermogram of Entacapone exhibited a sharp 
endotherm melting point at 1610C. The thermo gram of optimized 
formulation of Entacapone exhibited a sharp endotherm melting 
point at 164 0C.The DSC thermo gram retained properties of 
Entacapone, as well as polymer properties. There is no 
considerable change observed in melting endotherm of drug in 
optimized formulation (Figure 9). It indicates that there is no 
interaction between drug & excipients used in the formulation. 
Stability studies 
Optimized formulation was selected for stability studies on the 
basis of high cumulative % drug release. Stability studies were 
conducted for 6 months according to ICH guidelines. From these 
results it was concluded that, optimized formulation is stable and 
retained their original properties with minor differences which 
depicted in Table 9. 
 
     Table 9: Physico-chemical characteristics of optimized formulation HF14 
 Retest Time For Optimized formulation Friability (%) Hardness (kg/cm2) % Drug content In-vitro drug release profile (%)
Initial 0.22 7.2 98.9 98.29
40ĈC/75%RH 
1st month 0.25 7.3 98.04 97.10
2nd month  0.28 7.3 97.25 96.65
 3rd month 0.31 7.4 96.15 96.5
6th month 0.34 7.5 95.18 95.5
25ĈC/60%RH  3rd month 0.26 7.2 98.8 96.2
6th month 0.29 7.3 98.7 95.8
 
Pharmacokinetic studies 
 
 
Figure 10: Plasma Concentrations of Entacapone optimized formulation (HF14) and marketed product at different time intervals  
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Table 10: Comparison of pharmacokinetic parameters of Entacapone Optimized formulation (HF 14) and marketed product 
Parameters Entacapone optimized formulation (HF14) 
Marketed product 
Cmax (øg/ml) 
7826.21μ0.03 8308.29μ0.03 
AUC 0-t (øg h/ml) 
37386.12μ0.01 30458.19μ0.01 
AUC0-¥ (øg h/ml) 
41528.12μ0.02 34589.18μ0.02 
Tmax (h) 
4.01μ0.04 1.00μ0.01 
t 1/2 (h) 
6.25μ0.004 3.125μ0.05 
 
Bioavailability Parameters 
Mean plasma concentration profiles of prepared Entacapone 
optimized formulation and Marketed product are presented in 
Figure 10. Entacapone optimized formulation exhibited as 
sustained release in vivo when compared with Marketed product. 
All the pharmacokinetics parameters displayed in Table 10. 
Entacapone reference drug was available in plasma within an hour 
after its oral administration. The Tmax of the optimized formulation 
was significantly different (p < 0.05) from that of the marketed 
product. Low Tmax value for the reference drug (1.00μ0.01h) 
indicates rapid absorption while the higher Tmax of the test drug 
(4.01μ0.04h) suggests slower absorption. This delayed absorption 
of test preparation is most likely due to the sustained release of the 
drug. On the other hand, the Cmax of reference formulation was 
significantly different from the test preparation. The half-life of the 
reference preparation was low which indicates rapid removal of the 
drug from plasma. This was also supported by the high elimination 
rate constant value. On the other hand, the test formulation 
exhibited higher half-life and low elimination rate constant values 
indicating slower drug disposition and prolonged effect. However, 
the AUC0-¥ values for the two formulations were significantly 
different. This suggests that the Entacapone contained in the test 
product was completely absorbed. 
Summary and conclusion 
It was concluded that trilayer matrix tablets of Entacapone can be 
successfully prepared by direct compression technique using 
different polymers combination. Based on the evaluation 
parameters, drug dissolution profile and release drug kinetics HF14 
was found to be optimized formulation. The drug release from 
HF14 was found to fit Zero order of concentration independent and 
best fitted to HiguchiÊs model confirming to be diffusion assisted 
mechanism. The marketed product release was explained by first 
order kinetics by concentration dependent. In vivo bioavailability 
studies were conducted for optimized Entacapone trilayer tablets 
and marketed product, the results were indicating that the 
optimized Entacapone formulation was shown sustained release 
patterns where marketed product was shown immediate release. 
So the optimized formulation was shown significant plasma 
concentrations with controlled release and maintained for 24 hrs. 
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